Mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks was administered to 15 evaluable patients with measurable advanced soft tissue sarcomas resistant to standard treatment. No response was observed. Disease stabilization occurred in 5 patients, with a median duration of 4 months. Toxicity was generally mild to moderate. On the basis of this study, mitomycin C, in the dosage and schedule used in the above study, cannot be recommended in the treatment of this disease.
|Translated title of the contribution||Mitomycin C in treatment of advanced soft-tissue sarcomata in adults|
|Number of pages||3|
|Publication status||Published - 1985|
ASJC Scopus subject areas